Shopping Cart
- Remove All
Your shopping cart is currently empty
BAY-8400
🥰Excellent
Catalog No. T9498
BAY-8400 is a potent, selective, and orally active DNA-dependent protein kinase (DNA-PK) inhibitor (IC50 = 81 nM) that demonstrates synergistic efficacy when combined with targeted alpha therapies. BAY-8400 is applicable for cancer research [1].
BAY-8400
🥰Excellent
Purity: 99.32%
Catalog No. T9498
BAY-8400 is a potent, selective, and orally active DNA-dependent protein kinase (DNA-PK) inhibitor (IC50 = 81 nM) that demonstrates synergistic efficacy when combined with targeted alpha therapies. BAY-8400 is applicable for cancer research [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $77 | In Stock | |
| 5 mg | $158 | In Stock | |
| 10 mg | $238 | In Stock | |
| 25 mg | $488 | In Stock | |
| 50 mg | $833 | In Stock | |
| 100 mg | $1,120 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $173 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BAY-8400"
LY294002
Cited
SF 1101, NSC 697286, LY 294002
T2008154447-36-6
LY294002 (SF 1101) is a broad-spectrum inhibitor of PI3K, inhibiting PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5/0.57/0.97 μM). LY294002 is also an inhibitor of DNA-PK (IC50=1.4 μM) and an inhibitor of CK2 (IC50=98 nM). LY294002 activates apoptosis and autophagy.
- $34
Size
QTY
CitedSTL127705
Compound L, 7-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-3-(3-fluorophenyl)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione
T130171326852-06-5In house
STL127705 (Compound L) is a potent inhibitor of the Ku 70/80 heterodimer protein, disrupting Ku70/80-DNA interaction with an IC50 of 3.5 μM, and inhibiting Ku-dependent DNA-PKCS kinase activation with an IC50 of 2.5 μM.
- $116
Size
QTY
NU6027
T6612220036-08-8
NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.
- $37
Size
QTY
YU238259
T43391943733-16-1
YU238259 is a novel inhibitor of homology-dependent DNA repair(HDR), but does not inhibit non-homologous end-joining (NHEJ), in cell-based GFP reporter assays.
- $40
Size
QTY
PI3K-IN-1
XL765, Voxtalisib Analogue, SAR245409
T18261349796-36-6
PI3K-IN-1 (Voxtalisib Analogue) is a dual inhibitor of mTOR/PI3K, mostly for p110γ , also inhibits DNA-PK and mTOR.
- $30
Size
QTY
KU-57788 Cited
NU7441
T6276503468-95-9
NU7441 (KU-57788 (NU7441)) is a highly effective and specific DNA-PK inhibitor (IC50: 14 nM).
- $34
Size
QTY
CitedPI-3065
PI3065
T2083955977-50-1
PI-3065 is a novel potent and selective PI3K p110δ inhibitor.
- $44
Size
QTY
Onatasertib
CC-223, CC223, CC 223
T33511228013-30-6
Onatasertib (CC223) is an orally available mTOR inhibitor with potential antitumor activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Onatasertib is a potent mTOR kinase inhibitor (IC50: 16 nM), with >150-fold sensitivity than the related lipid kinase PI3Kα (IC50: 4 μM).
- $35
Size
QTY
Compound 401
2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one
T3586168425-64-7
Compound 401 (2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one) is a synthetic DNA-PK inhibitor (IC50 = 0.28 μM) that also targets mTOR but not PI3K.
- $29
Size
QTY
Samotolisib
LY3023414, GTPL8918
T68831386874-06-1
Samotolisib (LY3023414) is an oral ATP competitive inhibitor of the class I PI3K isoforms, DNA-PK, and mTOR. Samotolisib (LY3023414) has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.
- $41
Size
QTY
Select Batch
Purity:99.32%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | BAY-8400 is a potent, selective, and orally active DNA-dependent protein kinase (DNA-PK) inhibitor (IC50 = 81 nM) that demonstrates synergistic efficacy when combined with targeted alpha therapies. BAY-8400 is applicable for cancer research [1]. |
| Targets&IC50 | DNA-PK:81 nM |
| In vivo | BAY-8400 (150 mg/kg; p.o.) increases the antitumor efficacy that even improved tumor-induced body weight loss. BAY-8400 shows useful aqueous solubility and oral bioavailability across species [1]. |
| Molecular Weight | 393.39 |
| Formula | C21H17F2N5O |
| Smiles | FC(F)C1=CN=CC(C2=CC=C(N=CC3=NN=C(C4=CCCOCC4)N35)C5=C2)=C1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (152.52 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BAY-8400 | purchase BAY-8400 | BAY-8400 cost | order BAY-8400 | BAY-8400 chemical structure | BAY-8400 in vivo | BAY-8400 formula | BAY-8400 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.